This document summarizes the work of Biofab, a company that aims to reduce organ transplant waiting lists by developing bio-generated organs using 3D bioprinting and stem cell technology. Biofab was founded by Cesar Loo and plans to develop organ bioprinting models using stem cells from umbilical cords, teeth, and adipose tissue. Their strategy is to establish operations in Europe and sell bioprinters, biomaterials, and stem cells to eventually bioprint tracheas, esophagi, and bladders for human transplant.

1. www.biofab.com.pe
USA – Chile - Peru
Mexico - The Netherlands

2. Reducing organ transplantaBon
waiBng lists by providing
bio-generated organs
ABOUT US
Cesar Loo – Founder
Gaby – Co-Founder
Ricardo Garcia – InternaBonal PR

3. A paBent waiBng for an organ
Time - Stress - Pain
PROBLEM

4. Reducing organ transplantaBon waiBng lists
by providing bio-generated organs
OUR CORE PURPOSE

5. OBSTACLE
HIGH COST COMPATIBLE ORGAN BLOOD TYPE

6. STRATEGY

7. BUSINESS MODELS
Bank of Organ - CryopreservaBon of umbilical cord stem
cells, adipose Bssue and the third molar.DifferenBaBon and
mulBplicaBon of stem cells
Classes for protocols of extracBon, differenBaBon,
cryopreservaBon and stem cell applicaBon.
BioPrinter Biofab sales.

8. 3d Printer Stem Cell
Technology
Organ transplant
1. Umbilical cord
2. Third molar and
baby teeth
3. Adipose Bssue
Umbilical cord
Low Cost
3d Printer Stem Cell
Technology
COMPETITORS

9. Biofab will increase human life duraBon
44100 die while officially placed
on these waiBng lists
PLACED ON
ORGAN
WAITING LIST
wait for a new organ transplanta/on
263,000 people in Europe

10. Sell organs: traquea, esophagus, bladder
Kit: Bioprinter, biogel, stem cells, bioreactor
LEARNED AT BRIGHTLANDS INNOVATION FACTORY

11. University of Maastricht –
Dr. Lorenzo Moroni, Professor in BiofabricaBon
Noviocell – PhD Julie^e Van den Dolder
VALIDATION

12. THE OPPORTUNITY
StarBng a company (BV) in The Nethetlands, at Brightlands
to have the operaBon center for Europe

13. Agreement
UPCH
MulBdent
Hospitales Angeles
Today
Scale
Chile
Mexico
USA
World Tour
Show BioPrinter in Tech Fairs
Oct 2016
First Transplant
Esophagus Transplant in Human
Nov - 2016 2014
2015
2016
ROADMAP
2017

14. 28%
42%
21%
9%
MarkeBng Team
Use Sales
Currently Sales
$205,000.00 [Customers]
• 200 Clients
• 57 Criopreservates Stem Cells
• 03 Agreements with UniversiBes
Achievements to Date
• Incorporate BioFab in USA. BioFab Inc
• 1 Patent
• Incorporated BioFab in Peru, Chile, Mexico and The
Netherlands
• BioPrinter Final Version
• 3 Ordes BioPrinters in Rusia, Canada and Thailand
TRACTION

15. Reducing organ transplantaBon
waiBng lists, by providing
biogenerated organs
THANK YOU
For your A^enBon